NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
39 trialsNCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06631326 2026-01-27
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
First Hospital of China Medical University
Completed
NCT05254847 2026-01-20
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Fudan University
Phase 2 Completed
NCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed
NCT05342636 2025-12-17
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03797326 2025-11-17
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05091346 2025-10-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05101629 2025-07-23
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03781934 2025-07-01
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Medivir
Phase 1/2 Completed
NCT03609359 2025-04-16
Lenva+Pembro
National Cancer Center Hospital East
Phase 2 Completed
NCT04401800 2025-03-10
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
BeiGene
Phase 2 Completed
NCT05303090 2025-02-27
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
Fudan University
Phase 1 Completed
NCT05010668 2025-02-21
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2 Completed
NCT04361331 2025-02-07
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT05003700 2024-11-05
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT04763408 2024-07-18
STELLAR
Eisai Inc.
Completed
NCT03418922 2024-06-20
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1 Completed
NCT06435013 2024-05-30
Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
Sun Yat-sen University
Completed
NCT04444167 2024-04-25
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
Akeso
Phase 1/2 Completed
NCT03321630 2024-03-27
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
NYU Langone Health
Phase 2 Completed
NCT04618367 2024-03-06
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Phase NA Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT03006926 2023-12-13
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1 Completed
NCT04297254 2023-11-15
A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
Eisai Inc.
Phase 4 Completed
NCT04642547 2023-08-01
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
RenJi Hospital
Phase NA Completed
NCT04044313 2023-06-12
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Completed
NCT03841201 2023-05-12
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03895970 2023-03-29
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Peking Union Medical College Hospital
Phase 2 Completed
NCT05307926 2022-09-07
Postoperative Adjuvant Therapy of HCC Based on PD-1
Tongji Hospital
Completed
NCT02935309 2022-05-31
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT04008082 2022-03-08
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Completed
NCT04656249 2021-06-04
LENABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT03663114 2021-01-22
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Completed
NCT02579616 2020-12-23
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT04415567 2020-06-04
Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Completed
NCT00946153 2019-02-01
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Eisai Inc.
Phase 1/2 Completed